SCHEMBL3021348

SCHEMBL3021348

Cc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
USP2 O75604 2/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TP53 P04637 1/20 0.41
LMNA P02545 5/20 0.41
TSHR P16473 5/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
HTT P42858 3/20 0.41
MAPK1 P28482 3/20 0.41
POLB P06746 2/20 0.41
GAA P10253 1/20 0.41
GBA1 P04062 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
CNR1 P21554 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016087 0.94 LMNA (0.47) MAPTUSP2RECQLHSD17B10TP53
SCHEMBL3011545 0.92 ALDH1A1 (0.47) MAPTUSP2RECQLHSD17B10TP53
SCHEMBL3014631 0.92 GBA1 (0.44) MAPTUSP2RECQLHSD17B10LMNA
SCHEMBL3013030 0.90 MEN1 (0.46) MAPTUSP2RECQLHSD17B10TP53
SCHEMBL3014213 0.89 KMT2A (0.43) MAPTUSP2RECQLHSD17B10TP53
SCHEMBL3010517 0.89 TSHR (0.49) MAPTUSP2RECQLHSD17B10TP53
SCHEMBL3015352 0.88 MAPT (0.43) MAPTUSP2TP53LMNATSHR
SCHEMBL3018408 0.88 TRPV4 (0.43) MAPTUSP2RECQLHSD17B10TP53
SCHEMBL3006628 0.87 HTT (0.47) MAPTUSP2RECQLHSD17B10TP53
SCHEMBL3016091 0.87 TSHR (0.48) MAPTUSP2LMNATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.